From OpenWetWare
Jump to navigationJump to search


Home                  Research                  Lab Members                  Publications                  JC                      Links                  Internal                  Contact                 


W Office (10am - )

Name Year
6/11 Research (혜령), JC (정민)
7/9 Research (정민), JC (혜령)
7/23 Research (혜령, 성수), JC (정민)
8/13 Research (정민), JC (혜령)
8/27 Research (혜령), JC (정민)

Past papers


  1. Talamini L, Violatto MB, Cai Q, Monopoli MP, Kantner K, Krpetić Ž, Perez-Potti A, Cookman J, Garry D, P Silveira C, Boselli L, Pelaz B, Serchi T, Cambier S, Gutleb AC, Feliu N, Yan Y, Salmona M, Parak WJ, Dawson KA, and Bigini P. Influence of Size and Shape on the Anatomical Distribution of Endotoxin-Free Gold Nanoparticles. ACS Nano. 2017 Jun 27;11(6):5519-5529. DOI:10.1021/acsnano.7b00497 | PubMed ID:28558193 | HubMed [Talamini2017]
  2. Henriksen U, Gether U, and Litman T. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. DOI:10.1242/jcs.01729 | PubMed ID:15769853 | HubMed [Henriksen2005]
  3. Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, and Bota DA. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 2016 Jun;18(6):840-8. DOI:10.1093/neuonc/nov299 | PubMed ID:26681765 | HubMed [Di2016]
  4. Woodward OM, Tukaye DN, Cui J, Greenwell P, Constantoulakis LM, Parker BS, Rao A, Köttgen M, Maloney PC, and Guggino WB. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5223-8. DOI:10.1073/pnas.1214530110 | PubMed ID:23493553 | HubMed [Woodward2013]
  5. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, MacMillan P, Zhang Y, Rajesh NU, Hoang T, Wu JLY, Wilhelm S, Zilman A, Gadde S, Sulaiman A, Ouyang B, Lin Z, Wang L, Egeblad M, and Chan WCW. The entry of nanoparticles into solid tumours. Nat Mater. 2020 May;19(5):566-575. DOI:10.1038/s41563-019-0566-2 | PubMed ID:31932672 | HubMed [Sindhwani2020]
  6. Hoque KM, Dixon EE, Lewis RM, Allan J, Gamble GD, Phipps-Green AJ, Halperin Kuhns VL, Horne AM, Stamp LK, Merriman TR, Dalbeth N, and Woodward OM. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat Commun. 2020 Jun 2;11(1):2767. DOI:10.1038/s41467-020-16525-w | PubMed ID:32488095 | HubMed [Hoque2020]
  7. Liu S, Ono RJ, Yang C, Gao S, Ming Tan JY, Hedrick JL, and Yang YY. Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery. ACS Appl Mater Interfaces. 2018 Jun 13;10(23):19355-19364. DOI:10.1021/acsami.8b01954 | PubMed ID:29757607 | HubMed [Liu2018]
  8. Ma Y, He P, Tian X, Liu G, Zeng X, and Pan G. Mussel-Derived, Cancer-Targeting Peptide as pH-Sensitive Prodrug Nanocarrier. ACS Appl Mater Interfaces. 2019 Jul 10;11(27):23948-23956. DOI:10.1021/acsami.9b09031 | PubMed ID:31192575 | HubMed [Ma2019]
  9. Li Y, Hong W, Zhang H, Zhang TT, Chen Z, Yuan S, Peng P, Xiao M, and Xu L. Photothermally triggered cytosolic drug delivery of glucose functionalized polydopamine nanoparticles in response to tumor microenvironment for the GLUT1-targeting chemo-phototherapy. J Control Release. 2020 Jan 10;317:232-245. DOI:10.1016/j.jconrel.2019.11.031 | PubMed ID:31783048 | HubMed [Li2019]
  10. Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, and Wang Z. In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. Drug Metab Dispos. 2017 Jul;45(7):712-720. DOI:10.1124/dmd.117.075226 | PubMed ID:28428366 | HubMed [Wang2017]
  11. Li D, Zhang X, Ma X, Xu L, Yu J, Gao L, Hu X, Zhang J, Dong X, Li J, Liu T, Zhou Y, and Hu Y. Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors. J Med Chem. 2018 Oct 25;61(20):9177-9204. DOI:10.1021/acs.jmedchem.8b00819 | PubMed ID:30265557 | HubMed [Li2018]
All Medline abstracts: PubMed | HubMed


  1. Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, Wang Z. In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. Drug Metab Dispos. 2017 Jul;45(7):712-720 (PMID: 28428366) (1/22/19, 나은).
  2. Schäfer AM, Potterat O, Seibert I, Fertig O, Meyer Zu Schwabedissen HE. Hyperforin-Induced Activation of the Pregnane X Receptor Is Influenced by the Organic Anion-Transporting Polypeptide 2B1. Mol Pharmacol. 2019 Mar;95(3):313-323. (PMID: 30573512) (2/8/19, 지윤)
  3. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009 Jul;15(7):781-7. doi: 10.1038/nm.1978. Epub 2009 Jun 14. Erratum in: Nat Med. 2009 Nov;15(11):1333. (PMID: 19525961) (3/5/19, 지수)
  4. Basseville A, Tamaki A, Ierano C, Trostel S, Ward Y, Robey RW, Hegde RS, Bates SE. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. Cancer Res. 2012 Jul 15;72(14):3642-51. (PMID: 22472121) (3/28/19, 정민)
  5. Liang J, Gao C, Zhu Y, Ling C, Wang Q, Huang Y, Qin J, Wang J, Lu W, Wang J. Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery. ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30201-30213. (PMID: 30113810) (4/16/19, 혜령)
  6. Michael Zimmermann, Maria Zimmermann-Kogadeeva, Rebekka Wegmann, Andrew L. Goodman. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019 Feb 8;363(6427). (PMID: 30733391) (5/3/19, 나은)
  7. Wagner LK, Gilling KE, Schormann E, Kloetzel PM, Heppner FL, Krüger E, Prokop S. Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice. Acta Neuropathol Commun. 2017 Jun 24;5(1):52. (PMID: 28646899) (6/4/19, 지수)
  8. Peng H, Zhu QS, Zhong S, Levy D. Transcription of the Human Microsomal Epoxide Hydrolase Gene (EPHX1) Is Regulated by PARP-1 and Histone H1.2. Association with Sodium-Dependent Bile Acid Transport. PLoS One. 2015 May 20;10(5):e0125318. (PMID: 25992604) (6/21/19, 선아)
  9. Ripperger A, Benndorf RA. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2. Biochem Pharmacol. 2016 Mar 15;104:139-47. (PMID: 26903388) (7/19/19, 정민)
  10. Jablonka L, Ashtikar M, Gao G, Jung F, Thurn M, Preuß A, Scheglmann D, Albrecht V, Röder B, Wacker MG. Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans.J Control Release. 2019 Jun 24;308:57-70. (PMID: 31247282) (8/2/19, 혜령)


  1. Sigfridsson K, Skantze P, Skantze U, Svensson L, Löfgren L, Nordell P, Michaëlsson E, Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L. Nanocrystal formulations of a poorly soluble drug. 2. Evaluation of nanocrystal liver uptake and distribution after intravenous administration to mice. Int J Pharm. 2017;524(1-2):248-256. (1/11/18, 지은)
  2. Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Alves NJ, Suzuki R, Kikuchi S, Hideshima T, Anderson KC, Kiziltepe T, Bilgicer B. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. J Control Release. 2014;196:113-21 (PMID: 25312543) (3/6/18, Yearin)
  3. Koslowski M1, Luxemburger U, Türeci O, Sahin U. Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α. Oncogene. 2011;30(7):876-82. (PMID: 21042279) (3/20/18, Naeun)
  4. Keiser M, Kaltheuner L, Wildberg C, Müller J, Grube M, Partecke LI, Heidecke CD, Oswald S. The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers. J Pharm Sci.2017;106(9):2657-2663. (PMID: 28408210) (4/3/18, JiYoon)
  5. Weyburne ES, Wilkins OM, Sha Z, Williams DA, Pletnev AA, de Bruin G, Overkleeft HS, Goldberg AL, Cole MD, Kisselev AF. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.Cell Chem Biol. 2017;24(2):218-230. (PMID: 28132893) (5/1/18, ZiSoo)
  6. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.J Pharmacol Exp Ther. 2009 Feb;328(2):652-62 (06/05/18, Jieun)
  7. Kasai T, Nakanishi T, Ohno Y, Shimada H, Nakamura Y, Arakawa H, Tamai I. Role of OATP2A1 in PGE(2) secretion from human colorectal cancer cells via exocytosis in response to oxidative stress. Exp Cell Res. 2016;341(2):123-31. (7/6/18, Jiyoon)
  8. Hoang B, Ernsting MJ, Roy A, Murakami M, Undzys E, Li SD. Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. Biomaterials. 2015 Aug;59:66-76. (PMID: 25956852) (7/24/18, HR)
  9. Biao Deng, Lei Qu, Jinfang Li, Jiaqing Fang, Shouwen Yang, Zhongwei Cao, Zhechuan Mei, and Xing Sunb. MiRNA-211 suppresses cell proliferation, migration and invasion by targeting SPARC in human hepatocellular carcinoma. Sci Rep. 2016; 6: 26679. (PMID: 27230656) (8/7/18, JM)
  10. Sun Y, Piñón Hofbauer J, Harada M, Wöss K, Koller U, Morio H, Stierschneider A, Kitamura K, Hashimoto M, Chiba K, Akita H, Anzai N, Reichelt J, Bauer JW, Guttmann-Gruber C, Furihata T. Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technology. Cancer Lett. 2018 Oct 1;433:107-116. (PMID: 29960051) (8/29/18, Naeun)

For <약제학특론 II>

  1. Ferreira M, Chaves LL, Lima SA, Reis S. Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy.Int J Pharm. 2015 Aug 15;492(1-2):65-72. (PMID: 26169145) (10/08/18, 김민환)
  2. He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, Lin W. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016 Aug 17;7:12499. (PMID: 27530650) (10/08/18, 백민준)
  3. Chen M, Kumar S, Anselmo AC, Gupta V, Slee DH, Muraski JA, Mitragotri S. Topical delivery of Cyclosporine A into the skin using SPACE-peptide. J Control Release. 2015 Feb 10;199:190-7. (PMID: 25481447) (10/15/18, 김규호)
  4. Hirota K, Doty AC, Ackermann R, Zhou J, Olsen KF, Feng MR, Wang Y, Choi S, Qu W, Schwendeman AS, Schwendeman SP. Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation. J Control Release. 2016 Dec 28;244(Pt B):302-313. (PMID: 27565212) (10/22/18, 김관영)
  5. Li D, Zhang X, Ma X, Xu L, Yu J, Gao L, Hu X, Zhang J, Dong X, Li J, Liu T, Zhou Y, Hu Y. Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors. J Med Chem. 2018 Oct 25;61(20):9177-9204. (PMID: 30265557) (10/22/18, 유지수)
  6. Andersen MØ, Lichawska A, Arpanaei A, Rask Jensen SM, Kaur H, Oupicky D, Besenbacher F, Kingshott P, Kjems J, Howard KA. Surface functionalisation of PLGA nanoparticles for gene silencing.Biomaterials. 2010 Jul;31(21):5671-7. (PMID: 20434215) (10/29/18, 최용주)
  7. Yang Lu, Zhanguo Yue, Jinbing Xie, Wei Wang, Hui Zhu, Ershuai Zhang & Zhiqiang Cao. Micelles with ultralow critical micelle concentration as carriers for drug delivery. Nature Biomedical Engineeringvolume 2, pages318–325 (2018). (10/29/18, Thuc)
  8. Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T. Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. Mol Ther. 2018 Jul 5;26(7):1840-1854. (PMID: 29759938) (11/12/18, 윤나은)
  9. Fujita D, Arai T, Komori H, Shirasaki Y, Wakayama T, Nakanishi T, Tamai I. Apple-Derived Nanoparticles Modulate Expression of Organic-Anion-Transporting Polypeptide (OATP) 2B1 in Caco-2 Cells. Mol Pharm. 2018 Nov 5. (PMID: 30359033) (11/12/18, 최지윤)
  10. Butler JS, Chan A, Costelha S, Fishman S, Willoughby JL, Borland TD, Milstein S, Foster DJ, Gonçalves P, Chen Q, Qin J, Bettencourt BR, Sah DW, Alvarez R, Rajeev KG, Manoharan M, Fitzgerald K, Meyers RE, Nochur SV, Saraiva MJ, Zimmermann TS. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.Amyloid. 2016 Jun;23(2):109-18. (PMID: 27033334) (11/19/18, 전혜진)
  11. Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94. (PMID: 24037730) (11/19/18, 안소윤)


  1. Kang T, Zhu Q, Wei D, Feng J, Yao J, Jiang T, Song Q, Wei X, Chen H, Gao X, Chen J.Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis. ACS Nano. 2017 Jan 26. doi: 10.1021/acsnano.6b06477. (PMID: 28075552) (2/14/17 JP)
  2. Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J, He Y, Wu J, Zhang Z, Liu Z. Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in hepatoma cells. Mol Cancer Ther. 2011 Jun;10(6):1113-23. (PMID: 21460102) (3/14/17, GM)
  3. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids. 2016;5:e399. doi: 10.1038/mtna.2016.103. (PMID: 28131283) (3/28/17, YR)
  4. Hutt DM, Roth DM, Vignaud H, Cullin C, Bouchecareilh M. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One. 2014 Aug 28;9(8):e106224. doi: 10.1371/journal.pone.0106224. eCollection 2014. (PMID: 25166596) (4/18/17, GM)
  5. V. Tong, F.S. Abbott, S. Mbofana, M.J. Walker, In vitro investigation of the hepatic extraction of RSD1070, a novel antiarrhythmic compound, J Pharm Pharm Sci 4(1) (2001) 15-23 (PMID: 11302786) (5/10/17, YO)
  6. J. Schafer, L. Welti, A. Seckinger, J. Burhenne, D. Theile, J. Weiss, Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient, Cancer Chemother Pharmacol (2017) (PMID: 28500557) (5/23/17, JP).
  7. Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, Heller DA. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med. 2016 Jun 29;8(345):345ra87.(PMID: 27358497) (6/13/17, YR)
  8. Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. (7/4/17, 지수)
  9. Fujita T, Doihara H, Washio K, Kawasaki K, Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y, Shimizu N. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs. 2006 Apr;17(4):455-62 (7/4/17, 나은).
  10. Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, Yoshimura T. Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice. Drug Metab Dispos. 2010 Mar;38(3):526-33. (PMID: 20007293) (8/16/17, 공미)
  11. Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, Kobayashi K, Chiba K. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64. doi: 10.1128/AAC.02724-14. (PMID: 24867984) (8/30/17, 윤석)
  12. Park J, Sun B, Yeo Y. Albumin-coated nanocrystals for carrier-free delivery of paclitaxel. J Control Release. 2017 Oct 10;263:90-101. doi: 10.1016/j.jconrel.2016.12.040. (PMID: 28049022) (9/20/17, 지은)
  13. Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, Wang Z. In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. Drug Metab Dispos. 2017 Jul;45(7):712-720 (PMID: 28428366) (10/11/17, 예린).
  14. Gou J, Liang Y, Miao L, Guo W, Chao Y, He H, Zhang Y, Yang J, Wu C, Yin T, Wang Y, Tang X. Improved tumor tissue penetration and tumor cell uptake achieved by delayed charge reversal nanoparticles. Acta Biomater. 2017 Oct 15;62:157-166. doi: 10.1016/j.actbio.2017.08.025. (10/25/17, 민준)
  15. Ling L, Du Y, Ismail M, He R, Hou Y, Fu Z, Zhang Y, Yao C, Li X. Self-assembled liposomes of dual paclitaxel-phospholipid prodrug for anticancer therapy. Int J Pharm. 2017 ;526(1-2):11-22. (11/8/17, Thuc)


  1. Reiner T, Parrondo R, de Las Pozas A, Palenzuela D, Perez-Stable C. Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. PLoS One. 2013;8(2):e56234. doi: 10.1371/journal.pone.0056234. (1/12/16, 지은)
  2. Ramachandran A, Betts G, Bhana S, Helme G, Blick C, Moller-Levet C, Saunders E, Valentine H, Pepper S, Miller CJ, Buffa F, Harris AL, West CM. An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. Eur J Cancer. 2013 May;49(7):1741-51. doi: 10.1016/j.ejca.2012.12.003. PMID: 23352438 (2/22/16, 송희)
  3. Chan T, Cheung FS, Zheng J, Lu X, Zhu L, Grewal T, Murray M, Zhou F. Casein kinase 2 is a novel regulator of the human organic anion transporting polypeptide 1A2 (OATP1A2) trafficking. Mol Pharm. 2016 Jan 4;13(1):144-54. doi: 10.1021/acs.molpharmaceut.5b00576. PMID: 26580496 (3/15/16, 세은)
  4. He X, Wang J, Wei W, Shi M, Xin B, Zhang T, Shen X. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. Cancer Biol Ther. 2016 Jan 19:1-11. PMID: 26785721 (3/29/16, 윤석)
  5. Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R, Auwerx J. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. PMID: 18307294 (4/19/16, 공미)
  6. Morgan JA, Lynch J, Panetta JC, Wang Y, Frase S, Bao J, Zheng J, Opferman JT, Janke L, Green DM, Chemaitilly W, Schuetz JD. Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death. Sci Rep. 2015 Nov 18;5:16488. PMID: 26576726 (5/16/16, 지은)
  7. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004 Jun 4;279(23):24218-25. PMID: 15044468 (5/27/16, 송희)
  8. Bakos E, Evers R, Calenda G, Tusnády GE, Szakács G, Váradi A, Sarkadi B. Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J Cell Sci. 2000 Dec;113 Pt 24:4451-61. PMID: 11082039 (6/28/16, 세은)
  9. Wang X, Tang Y, Lu J, Shao Y, Qin X, Li Y, Wang L, Li D, Liu M. Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9. Biochem Pharmacol. 2016 Apr 1;105:80-90. PMID: 26947455 (7/12/16, 민경)
  10. Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, Koeppen H, Leabman M, Iyer S. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016 Apr;8(3):593-603. PMID: 26918260 (7/27/16, 연희)
  11. To KK, Leung WW, Ng SS. A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development. Mol Carcinog. 2016 Jun 2. PMID: 27253631 (8/9/16, 윤석)
  12. Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 2011 Oct;54(4):1421-32. PMID: 21735468 (9/23/16, 공미)
  13. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, Kung AL, Hide W, Ince TA, Lieberman J. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013 Aug 12;24(2):182-96. PMID: 23948298 (10/11/16, 지은)
  14. Kasai T, Nakanishi T, Ohno Y, Shimada H, Nakamura Y, Arakawa H, Tamai I. Role of OATP2A1 in PGE2 secretion from human colorectal cancer cells via exocytosis in response to oxidative stress. Exp Cell Res. 2016 Feb 15;341(2):123-31. PMID: 26850138 (11/1/16, 세은)


  1. Errasti-Murugarren E, Casado FJ, Pastor-Anglada M. Different N-terminal motifs determine plasma membrane targeting of the human concentrative nucleoside transporter 3 in polarized and nonpolarized cells. Mol Pharmacol. 2010 Nov;78(5):795-803. doi: 10.1124/mol.110.065920. PMID: 20643903 (7/5/15, 세은)
  2. Imai S, Kikuchi R, Tsuruya Y, Naoi S, Nishida S, Kusuhara H, Sugiyama Y. Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res. 2013 Nov;30(11):2880-90. doi: 10.1007/s11095-013-1117-1. PMID: 23812637 (7/22/15, 윤석)
  3. Arakawa H, Nakanishi T, Yanagihara C, Nishimoto T, Wakayama T, Mizokami A, Namiki M, Kawai K, Tamai I. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol. 2012 Oct 15;84(8):1070-7. doi: 10.1016/j.bcp.2012.07.026. PMID: 22864060 (8/5/15, 진아)
  4. Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. PMID: 21752943 (9/3/15, 지은)
  5. Schaffner CA, Mwinyi J, Gai Z, Thasler WE, Eloranta JJ, Kullak-Ublick GA. The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes. Liver Int. 2015 Apr;35(4):1152-61. doi: 10.1111/liv.12558. PMID: 24703425 (9/18/15, 윤석)
  6. Kim D, Ko P, You E, Rhee S. The intracellular juxtamembrane domain of discoidin domain receptor 2 (DDR2) is essential for receptor activation and DDR2-mediated cancer progression. Int J Cancer. 2014 Dec 1;135(11):2547-57. doi: 10.1002/ijc.28901. PMID: 24740739 (10/12/15, 송희)
  7. Hong M, Hong W, Ni C, Huang J, Zhou C.Protein kinase C affects the internalization and recycling of organic anion transporting polypeptide 1B1. Biochim Biophys Acta. 2015;1848(10 Pt A):2022-30. doi: 10.1016/j.bbamem.2015.05.011. (10/26/15, 세은)
  8. Shen S, Du XJ, Liu J, Sun R, Zhu YH, Wang J. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. J Control Release. 2015 Jun 28;208:14-24. doi: 10.1016/j.jconrel.2014.12.043. (11/23/15, 지은)
  9. Heink S, Fricke B, Ludwig D, Kloetzel PM, Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. PMID: 16423992 (12/7/15, 송희)
  10. Hong W, Wu Z, Fang Z, Huang J, Huang H, Hong M. Amino Acid Residues in the Putative Transmembrane Domain 11 of Human Organic Anion Transporting Polypeptide 1B1 Dictate Transporter Substrate Binding, Stability, and Trafficking. Mol Pharm. 2015 Dec 7;12(12):4270-6. doi: 10.1021/acs.molpharmaceut.5b00466. (12/21/15, 세은)


  1. Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One. 2013 Oct 29;8(10):e77608. doi: 10.1371/journal.pone.0077608. (1/16/14 JEP)
  2. Subramanian VS, Marchant JS, Said HM. Apical membrane targeting and trafficking of the human proton-coupled transporter in polarized epithelia. Am J Physiol Cell Physiol. 2008 Jan;294(1):C233-40. (2/13/14, NT)
  3. Fabre B1, Lambour T, Delobel J, Amalric F, Monsarrat B, Burlet-Schiltz O, Bousquet-Dubouch MP. Subcellular distribution and dynamics of active proteasome complexes unraveled by a workflow combining in vivo complex cross-linking and quantitative proteomics. Mol Cell Proteomics. 2013 Mar;12(3):687-99. (2/17/14, KCC)
  4. Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol. 2014 Jan 13;7(1):7. (3/13/14, MJL)
  5. Pack CG, Yukii H, Toh-e A, Kudo T, Tsuchiya H, Kaiho A, Sakata E, Murata S, Yokosawa H, Sako Y, Baumeister W, Tanaka K, Saeki Y. Quantitative live-cell imaging reveals spatio-temporal dynamics and cytoplasmic assembly of the 26S proteasome. Nat Commun. 2014 Mar 6;5:3396. doi: 10.1038/ncomms4396.(PMID: 24598877) (3/27/14, LA)
  6. Raule M, Cerruti F, Benaroudj N, Migotti R, Kikuchi J, Bachi A, Navon A, Dittmar G, Cascio P. PA28αβ Reduces Size and Increases Hydrophilicity of 20S Immunoproteasome Peptide Products. Chem Biol. 2014 Apr 24;21(4):470-80. doi: 10.1016/j.chembiol.2014.02.006. Epub 2014 Mar 13. (PMID: 24631123) (4/17/14, ZM)
  7. Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, Zhang P, Xiao J, Zhang B, Li X. Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun. 2013;4:2667. doi: 10.1038/ncomms3667. (PMID: 24157709) (5/1/14, KCC)
  8. Crawford LJ, Chan ET, Aujay M, Holyoake TL, Melo JV, Jorgensen HG, Suresh S, Walker B, Irvine AE. Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis. 2014 (PMID: 24590311) (6/5/14, MJL)
  9. Wang P1, Wang JJ, Xiao Y, Murray JW, Novikoff PM, Angeletti RH, Orr GA, Lan D, Silver DL, Wolkoff AW. Interaction with PDZK1 is required for expression of organic anion transporting protein 1A1 on the hepatocyte surface. J Biol Chem. 2005 Aug 26;280(34):30143-9. (6/19/14, NT)
  10. Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10287-92. (7/10/14, LA)
  11. Gohlke S, Kloss A, Tsokos M, Textoris-Taube K, Keller C, Kloetzel PM, Dahlmann B. Adult human liver contains intermediate-type proteasomes with different enzymatic properties. Ann Hepatol. 2014 Jul-Aug;13(4):429-38. (7/24/14, JP)
  12. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014 Jan 17;343(6168):301-5. (8/07/14, KCC)
  13. Liu Z, Chen P, Gao H, Gu Y, Yang J, Peng H, Xu X, Wang H, Yang M, Liu X, Fan L, Chen S, Zhou J, Sun Y, Ruan K, Cheng S, Komatsu M, White E, Li L, Ji H, Finley D, Hu R. Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell. 2014 Jul 14;26(1):106-20. doi: 10.1016/j.ccr.2014.05.015. PMID: 25026213 (9/5/14 MJL)
  14. Minoia M, Boncoraglio A, Vinet J, Morelli FF, Brunsting JF, Poletti A, Krom S, Reits E, Kampinga HH, Carra S. BAG3 induces the sequestration of proteasomal clients into cytoplasmic puncta: Implications for a proteasome-to-autophagy switch. Autophagy. 2014 Sep 1;10(9):1603-21. doi: 10.4161/auto.29409. Epub 2014 Jul 10. PMID: 25046115 (9/19/14, LA)
  15. Yu T, Tao Y, Yang M, Chen P, Gao X, Zhang Y, Zhang T, Chen Z, Hou J, Zhang Y, Ruan K, Wang H, Hu R. Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis. Cell Res. 2014 Oct;24(10):1214-30. doi: 10.1038/cr.2014.122. Epub 2014 Sep 16. PMID: 25223703 (10/10/14, JP)


  1. Pinilla-Macua I, Casado FJ, Pastor-Anglada M. Structural determinants for rCNT2 sorting to the plasma membrane of polarized and non-polarized cells. Biochem J. 2012 Mar 15;442(3):517-25. doi: 10.1042/BJ20110605. (1/7/13 NT)
  2. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53 (2/4/13 YRL)
  3. Ramachandran A, Betts G, Bhana S, Helme G, Blick C, Moller-Levet C, Saunders E, Valentine H, Pepper S, Miller CJ, Buffa F, Harris AL, West CM. An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. Eur J Cancer. 2013 Jan 23. doi:pii: S0959-8049(12)00960-4. 10.1016/j.ejca.2012.12.003 (2/18/13, KBK)
  4. Maldonado M, Kapphahn RJ, MR Terluk, ND Heuss, C Yuan, DS Gregerson, DA Ferrington. Immunoproteasome Deficiency Modifies the Alternative Pathway of NFκB Signaling. Plos One 2013 (3/4/13, LA)
  5. Ali BR, Xu H, Akawi NA, John A, Karuvantevida NS, Langer R, Al-Gazali L, Leitinger B. Trafficking defects and loss of ligand binding are the underlying causes of all reported DDR2 missense mutations found in SMED-SL patients.Hum Mol Genet. 2010 Jun 1;19(11):2239-50. doi: 10.1093/hmg/ddq103. Epub 2010 Mar 10. (3/18/13, YRL)
  6. Knauer MJ, Girdwood AJ, Kim RB, Tirona RG. Transport Function and Transcriptional Regulation of a Liver-Enriched Human Organic Anion Transporting Polypeptide 2B1 Transcriptional Start Site Variant. Mol Pharmacol. 2013 Mar 26 (4/15/13, NT)
  7. Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood. 2011 Jan 27;117(4):1270-9. doi: 10.1182/blood-2010-04-278853. Epub 2010 Nov 24. (4/29/13, LA)
  8. Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis.Nat Cell Biol. 2013 May 5. doi: 10.1038/ncb2743. (5/13/13, W)
  9. Carafoli F, Mayer MC, Shiraishi K, Pecheva MA, Chan LY, Nan R, Leitinger B, Hohenester E. Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling.Structure. 2012 Apr 4;20(4):688-97. doi: 10.1016/j.str.2012.02.011. (6/10/13, YRL)
  10. Sun AQ, Salkar R, Sachchidanand, Xu S, Zeng L, Zhou MM, Suchy FJ. A 14-amino acid sequence with a beta-turn structure is required for apical membrane sorting of the rat ileal bile acid transporter. J Biol Chem. 2003 Feb 7;278(6):4000-9. (6/24/13, NT)
  11. Gohlke S, Mishto M, Textoris-Taube K, Keller C, Giannini C, Vasuri F, Capizzi E, D'Errico-Grigioni A, Kloetzel PM, Dahlmann B.Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities. Age (Dordr). 2013 May 22. [Epub ahead of print] PMID:23690132 (7/1/13, YW)
  12. Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell. 2013 Feb 28;152(5):1184-94 (7/15/13, KC)
  13. Lőw P, Varga A, Pircs K, Nagy P, Szatmári Z, Sass M, Juhász G. Impaired proteasomal degradation enhances autophagy via hypoxia signaling in Drosophila. BMC Cell Biol. 2013 Jun 25;14(1):29. doi: 10.1186/1471-2121-14-29. (PMID: 23800266)(8/12/13, DL)
  14. Zhu K, Dunner K Jr, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 2010 Jan 21;29(3):451-62. doi: 10.1038/onc.2009.343. (8/26/13, LA)
  15. Chou TF, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ.Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013 Feb;8(2):297-312. (9/9/13, ZM)
  16. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013 Sep 9;24(3):289-304. (9/23/13, JP)
  17. Zhang Q, Suh W, Pan Z, You G. Short-term and long-term effects of protein kinase C on the trafficking and stability of human organic anion transporter 3. Int J Biochem Mol Biol. 2012;3(2):242-9. (10/8/13 NT)
  18. Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk C, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J. Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors. Haematologica. 2013 Sep 20. PMID:24056819 (10/22/13, KC)
  19. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M.In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome. Mol Cancer Ther. 2013 Oct 29. (11/5/13, DH)
  20. Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K. Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128-350 triggers MM cell death via c-Jun upregulation. Cancer Lett. 2013 Oct 8. doi:pii: S0304-3835(13)00712-X. 10.1016/j.canlet.2013.09.042. (PMID:24120758) (11/19/13, MJL)
  21. Hasegawa M, Yasuda Y, Tanaka M, Nakata K, Umeda E, Wang Y, Watanabe C, Uetake S, Kunoh T, Shionyu M, Sasaki R, Shiina I, Mizukami T. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor. Eur J Med Chem. 2013 Nov 16;71C:290-305. doi: 10.1016/j.ejmech.2013.11.009. (12/3/13, ZM)
  22. Suraweera A, Münch C, Hanssum A, Bertolotti A. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell. 2012 Oct 26;48(2):242-53. doi: 10.1016/j.molcel.2012.08.003. (12/17/13, LA)


  1. Fang C, Dean J, Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 2007 Oct 1;67(19):9039-46. (pmid=17909007) (1/17/12 SH)
  2. Screen M, Britton M, Downey SL, Verdoes M, Voges MJ, Blom AE, Geurink PP, Risseeuw MD, Florea BI, van der Linden WA, Pletnev AA, Overkleeft HS, Kisselev AF. Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem. 2010 Dec 17;285(51):40125-34. Epub 2010 Oct 11. (1/31/12 DM)
  3. Kasuya K, Tsuchida A, Nagakawa Y, Suzuki M, Abe Y, Itoi T, Serizawa H, Nagao T, Shimazu M, Aoki T. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer ONCOLOGY REPORTS 26: 1399-1406, 2011 (2/14/12 NT)
  4. Heink S, Fricke B, Ludwig D, Kloetzel PM, Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. PMID:16423992 (2/28/12 JP)
  5. Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G. Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. Epub 2012 Jan 10. (3/13/12 KBj)
  6. Xu H, Fu J, Ha SW, Ju D, Zheng J, Li L, Xie Y. The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes. Biochim Biophys Acta. 2012 Apr;1823(4):818-25. Epub 2012 Jan 20. (3/27/12 LA)
  7. Jin L, Kikuchi R, Saji T, Kusuhara H, Sugiyama Y. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 α/β and DNA methylation.J Pharmacol Exp Ther. 2012 Mar;340(3):648-55. Epub 2011 Dec 7. (4/10/12 SH)
  8. Barretina J et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28;483(7391):603-7. (5/8/12 W)
  9. Degorter MK, Ho RH, Leake BF, Tirona RG, Kim RB. Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. Mol Pharm. 2012 Apr 2;9(4):986-95. Epub 2012 Mar 6. (PMID: 22352740) (5/33/12, NT)
  10. Fellerhoff B, Gu S, Laumbacher B, Nerlich AG, Weiss EH, Glas J, Kopp R, Johnson JP, Wank R. The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer Res. 2011 Dec 1;71(23):7145-54. Epub 2011 Oct 28. (PMID: 22037870) (6/5/12, JP)
  11. Errasti-Murugarren E, Molina-Arcas M, Casado FJ, Pastor-Anglada M. A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum. FASEB J. 2009 Jan;23(1):172-82. (PMID=18827020) (6/19/12, KBj)
  12. Wang Z, Sun Y. Identification and characterization of two splicing variants of human Noxa. Anticancer Res. 2008 May-Jun;28(3A):1667-74. (PMID=18630524) (7/2/12, YL)
  13. Higashimura Y, Nakajima Y, Yamaji R, Harada N, Shibasaki F, Nakano Y, Inui H. Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells. Arch Biochem Biophys. 2011 May 1;509(1):1-8. (PMID=21338575) (7/31/12 SHH)
  14. Errasti-Murugarren E, Casado FJ, Pastor-Anglada M. Different N-terminal motifs determine plasma membrane targeting of the human concentrative nucleoside transporter 3 in polarized and nonpolarized cells. Mol Pharmacol. 2010 Nov;78(5):795-803. (PMID=20643903 8/14/12 NT)
  15. Hammerman PS et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun;1(1):78-89. (PMID=22328973, 8/28/12 YRL)
  16. Heink S, Ludwig D, Kloetzel PM, Krüger E. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9241-6. (PMID: 15944226 9/10/12 KBj)
  17. Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, Bruzzese FJ, Barrett C, Liu JX, Soucy TA, Sappal DS, Bump N, Olhava EJ, Fleming P, Dick LR, Tsu C, Sintchak MD, Blank JL. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem J. 2010 Sep 15;430(3):461-76. (9/24/12 JP)
  18. Joeris T, Schmidt N, Ermert D, Krienke P, Visekruna A, Kuckelkorn U, Kaufmann SH, Steinhoff U. The proteasome system in infection: impact of β5 and LMP7 on composition, maturation and quantity of active proteasome complexes. PLoS One. 2012;7(6):e39827. (10/9/12 LA)
  19. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW.Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004 Sep;11(9):1028-37. PMID: 15131592 (10/22/12 NT)
  20. Yang K, Kim JH, Kim HJ, Park IS, Kim IY, Yang BS. Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. J Biol Chem. 2005 Nov 25;280(47):39058-66. (11/5/12 YRL)
  21. Mishto M, Santoro A, Bellavista E, Sessions R, Textoris-Taube K, Dal Piaz F, Carrard G, Forti K, Salvioli S, Friguet B, Kloetzel PM, Rivett AJ, Franceschi C. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol Chem. 2006 Apr;387(4):417-29. (PMID:16606340) (11/19/12 JP)
  22. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, Zhang X, Chung DC. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem. 2006;281(20):13957-63. (12/3/12, KBj)
  23. Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ. Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo. ACS Chem Biol. 2012 Dec 11. (12/17/11, LA)


  1. Unsworth H, Raguz S, Edwards HJ, Higgins CF, Yagüe E. mRNA escape from stress granule sequestration is dictated by localization to the endoplasmic reticulum. FASEB J. 2010 Sep;24(9):3370-80. (1/6/11 W)
  2. Weaver YM, Hagenbuch B. Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates. J Membr Biol. 2010 Aug;236(3):279-90. (2/14/11 NT)
  3. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science. 2010 Feb 19;327(5968):996-1000. (2/28/11 ERJ)
  4. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010 Aug;24(8):1506-12. (3/14/11 KHK)
  5. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011 Mar 1. (3/28/11 DHK)
  6. Meyer Zu Schwabedissen HE, Ware JA, Tirona RG, Kim RB. Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.Mol Pharm. 2009 Nov-Dec;6(6):1790-7. (4/18/11 NT)
  7. Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia. 2009 Jun;23(6):1098-105. (5/2/11 KHK)
  8. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Théate I, Parmentier N, Van den Eynde BJ. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. (PMID: 20937868) (6/6/11 ERJ)
  9. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009 May 14;52(9):3028-38. (PMID: 19348473) (6/20/11 WL)
  10. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics. 2011 Mar;21(3):103-14. (7/11/11 MA)
  11. Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennink JR, Yewdell JW. Unexpected Role for the Immunoproteasome Subunit LMP2 in Antiviral Humoral and Innate Immune Responses. J Immunol. 2010 Apr 15;184(8):4115-22. (PMID: 20228196) (8/22/11 ERJ)
  12. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G271-8. (9/19/11 NT)
  13. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol. 2009 Mar;296(3):C570-82. (10/3/11 JF)
  14. Martinez-Becerra P, Briz O, Romero MR, Macias RI, Perez MJ, Sancho-Mateo C, Lostao MP, Fernandez-Abalos JM, Marin JJ. Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol Pharmacol. 2011 Mar;79(3):596-607. (10/25/11 SHH)
  15. Mandery K, Sticht H, Bujok K, Schmidt I, Fahrmayr C, Balk B, Fromm MF, Glaeser H. Functional and structural relevance of conserved positively charged lysine residues in organic anion transporting polypeptide 1B3. Mol Pharmacol. 2011 Sep;80(3):400-6. (10/31/11 DM)
  16. Koslowski M, Luxemburger U, Türeci O, Sahin U. Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α. Oncogene. 2011 Feb 17;30(7):876-82. Epub 2010 Nov 1.
  17. Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, Lee CA. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug Metab Dispos. 2011 Nov;39(11):2093-102. Epub 2011 Aug 17.


  1. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009 Oct 15;114(16):3439-47. (pmid=19671918)
  2. Deborah J. Kuhn,1 Sally A. Hunsucker,1 Qing Chen,2 Peter M. Voorhees,2 Marian Orlowski,3 Robert Z. Orlowski1. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.Blood. 2009 May 7;113(19):4667-76. (pmid=19050304)
  3. Giada Bianchi,Laura Oliva,Paolo Cascio,5 Niccolo Pengo,Francesca Fontana, Fulvia Cerruti, Andrea Orsi,Elena Pasqualetto, Alexandre Mezghrani, Valeria Calbi, Giovanni Palladini, Nicola Giuliani, Kenneth C. Anderson,Roberto Sitia,and Simone Cenci. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26;113(13):3040-9 : 3040-3049.(pmid=19164601)
  4. Hideo Ohtsuka1, Takaaki Abe2,3, Tohru Onogawa1, Noriko Kondo1, Takeaki Sato1, Hiroshi Oshio1, Hiroya Mizutamari4, Tsuyoshi Mikkaichi3, Masaya Oikawa1, Toshiki Rikiyama1, Yu Katayose1, and Michiaki Unno1. Farnesoid X receptor, hepatocyte nuclear factors 1a and 3b are essential for transcriptional activation of the liver-specific organic anion. J Gastroenterol. 2006 Apr;41(4) : 369-77. (pmid=16741617)
  5. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. (pmid=18502982)
  6. Muñoz MJ, Pérez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, Glover-Cutter K, Ben-Dov C, Blaustein M, Lozano JJ, Bird G, Bentley D, Bertrand E, Kornblihtt AR. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell. 2009;137(4):708-20. (pmid=19450518)
  7. Vavricka SR, Jung D, Fried M, Grützner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol. 2004 Feb;40(2):212-8. (pmid=14739090)
  8. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007 Mar 2;354(1):154-9. (pmid=17214962)
  9. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008 Jan 1;103(1):270-83. (pmid=17516511)
  10. Imai S, Kikuchi R, Kusuhara H, Yagi S, Shiota K, Sugiyama Y. Analysis of DNA methylation and histone modification profiles of liver-specific transporters. Mol Pharmacol. 2009 Mar;75(3):568-576 (8/3/10)
  11. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells.Mol Cancer. 2010 May 18;9: 110(8/10/10)
  12. Kim SN, Kim NH, Lee W, Seo DW, Kim YK. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res. 2009 May;7(5):735-44 pmid=19435809 (9/16/10)
  13. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009 Mar 15;69(6):2305-13 pmid=19244107 (9/23/10)
  14. Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, and Tamai I. Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010 Oct; 122(4) 180-5(10/7/10)
  15. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, and Schinkel AH. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010 Aug 2; 120(8) 2942-52. doi:10.1172/JCI42168 pmid:20644253
  16. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB.Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 2008 Nov 15;68(22):9338-47.PMID: 19010908 (10/28/10)
  17. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW.Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004 Sep;11(9):1028-37. PMID: 15131592 (11/11/10)
  18. Guo Q, Chen Y, Wu Y. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1. Tumori. 2009 Nov-Dec;95(6):796-803. PMID: 20210246 (11/18/10)


  1. Fang C, Dean J, Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 2007 Oct 1;67(19):9039-46. (pmid=17909007)
  2. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, Ping P. Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics. 2009 Feb;8(2):302-15. (pmid=18931337)
  3. Gui C, Hagenbuch B. Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transportBiochemistry. 2008 Sep 2;47(35):9090-7. (pmid=18690707)
  4. Iorns E, Lord CJ, Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J. 2009 Jan 1;417(1):361-70. (pmid=18976239)
  5. Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N, Chiba T. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol. 2009 Apr;156(1):172-82. (pmid=19220323)
  6. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007 Oct;12(4):355-66. (pmid=17936560)
  7. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z, Cohen L, Danon T, Perzov N, Alon U. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008 Dec 5;322(5907):1511-6. (pmid=19023046)
  8. Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000 Apr 15;60(8):2090-4. (pmid=10786665)
  9. Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.Cancer Res. 2000 Apr 15;60(8):2090-4. (pmid=9751059)
  10. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):297-300.(pmid=9751060)
  11. Kravtsova-Ivantsiv Y, Cohen S, Ciechanover A. Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor. Mol Cell. 2009 Feb 27;33(4):496-504. (pmid=19250910)
  12. Shah K, Liu Y, Deirmengian C, Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3565-70. (pmid=9108016)
  13. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.Cancer Cell. 2007 Feb;11(2):119-32. (pmid=17292824)
  14. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 1998 Oct 29;395(6705):917-21. (pmid=9804427)
  15. Yang Z, Gagarin D, St Laurent G 3rd, Hammell N, Toma I, Hu CA, Iwasa A, McCaffrey TA. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1213-9. (pmid=19443843)
  16. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.Nature. 2004 Sep 23;431(7007):461-6. Epub 2004 Aug 25. (pmid=15329734)
  17. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.Hepatology. 2008 Nov;48(5):1632-43. (pmid=18972444)
  18. Nakagawa H, Tamura A, Wakabayashi K, Hoshijima K, Komada M, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem J. 2008 May 1;411(3):623-31.(pmid=18237272)
  19. Kimura Y, Yashiroda H, Kudo T, Koitabashi S, Murata S, Kakizuka A, Tanaka K. An inhibitor of a deubiquitinating enzyme regulates ubiquitin homeostasis.Cell. 2009 May 1;137(3):549-59. (pmid=19410548)
  20. Yi F, Regan L. A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol. 2008 Oct 17;3(10):645-54. Epub 2008 Sep 12.(pmid=18785742)
  21. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008 Sep 15;112(6):2489-99. (pmid=18565852)
  22. Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC Jr. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res. 2008 Aug 15;14(16):5116-23. (pmid=18698029)
  23. Voortman J, Checińska A, Giaccone G. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer. 2007 Nov 17;6:73. (pmid=18021420)
  24. Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschläger M, Strobl H. Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol. 2009 Jul 1;183(1):66-74. Epub 2009 Jun 17. (pmid=19535631)
  25. Shabek N, Herman-Bachinsky Y, Ciechanover A. Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11907-12. (pmid=19581590)
  26. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002 Jun 15;62(12):3387-94. (pmid=12067980)
  27. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003 Jan 9;22(1):90-7. (pmid=12527911)
  28. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. (pmid=17591945)
  29. Khan MA, Oubrahim H, Stadtman ER. Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11560-5. Epub 2004 Jul 29. (pmid=15284441)
  30. Xu M, Skaug B, Zeng W, Chen ZJ. A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol Cell. 2009 Oct 23;36(2):302-14. (pmid=19854138)
  31. Comerford KM, Cummins EP, Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004 Dec 15;64(24):9057-61. (pmid=15604272)